News | December 07, 2024
Briefs: Venus Remedies and GPT Healthcare
Venus Remedies secures marketing authorization in Philippines
Venus Remedies secures marketing authorization in Philippines
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
The celebrations began with the unveiling of the Biocon Anthem
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Subscribe To Our Newsletter & Stay Updated
